Leishmaniasis is listed by the World Health Organization as a neglected tropical disease. The medicines used to treat leishmaniasis are relatively expensive and therefore often unaffordable toxic. These drugs besides being toxic, confer resistance, few or no antileishmanial drugs are under development or have been approved for use recently. This review provides an overview of various synthetic compounds containing the sulfonamide group linked to heterocyclic rings that have been evaluated against Leishmania spp. and could be considered possible prototypes to develop new drugs to treat this disease.
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.